| 1. |
?Roorda BD, Ter Elst A, Kamps WA,et al. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol, 2009, 69(3): 187-198.
|
| 2. |
Kidd S, Spaeth E, Dembinski JL,et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments usingin vivo bioluminescent imaging. Stem Cells, 2009, 27(10): 2614-2623.
|
| 3. |
Nomoto-Kojima N, Aoki S, Uchihashi K,et al. Interaction between adipose tissue stromal cells and gastric cancer cellsin vitro. Cell Tissue Res, 2011, 344(2): 287-298.
|
| 4. |
Beckermann BM, Kallifatidis G, Groth A,et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer, 2008, 99(4): 622-631.
|
| 5. |
Block GJ, Ohkouchi S, Fung F,et al. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells, 2009, 27(3): 670-681.
|
| 6. |
Zhu W, Xu W, Jiang R,et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growthin vivo. Exp Mol Pathol, 2006, 80(3): 267-274.
|
| 7. |
Spaeth EL, Dembinski JL, Sasser AK,et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 2009, 4(4): e4992.
|
| 8. |
Okumura T, Wang SS, Takaishi S,et al. Identification of a bone marrow-derived mesenchymal progenitor cell subset that can contribute to the gastric epithelium. Lab Invest, 2009, 89(12): 1410-1422.
|
| 9. |
Uyttenhove C, Pilotte L, Théate I,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med, 2003, 9(10): 1269-1274.
|
| 10. |
Ren G, Zhang L, Zhao X,et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2008, 2(2): 141-150.
|
| 11. |
Zheng W, Seftor EA, Meininger CJ,et al. Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta. Am J Physiol Heart Circ Physiol, 2001, 280(2): H909-H917.
|
| 12. |
Rajantie I, Ilmonen M, Alminaite A,et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood, 2004, 104(7): 2084-2086.
|
| 13. |
Kalluri R, Neilson EG. Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest, 2003, 112(12): 1776-1784.
|
| 14. |
Martin FT, Dwyer RM, Kelly J,et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT) Breast Cancer Res Treat, 2010, 124(2): 317-326.
|
| 15. |
Kalluri R, Zeisberg M. Fibroblast in cancer. Nat Rev Cancer, 2006, 6(5): 392-401.
|
| 16. |
Simian M, Hirai Y, Navre M,et al. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development, 2001, 128(16): 3117-3131.
|
| 17. |
Orimo A, Gupta PB, Sgroi DC,et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 2005, 121(3): 335-348.
|
| 18. |
Nakamizo A, Marini F, Amano T,et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res, 2005, 65(8): 3307-3318.
|
| 19. |
Lu YR, Yuan Y, Wang XJ,et al. The growth inhibitory effect of mesenchymal stem cells on tumor cellsin vitro andin vivo. Cancer Biol Ther, 2008, 7(2): 245-251.
|
| 20. |
Zorzet S, Tripodo C. Human bone marrow mesenchymal stem cells display anticancer activity in SCID mice bearing disseminated non-Hodgkin’s lymphoma xenografts. PLoS One, 2010, 5(6): e11140.
|
| 21. |
Zhu Y, Sun Z, Han Q,et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia, 2009, 23(5): 925-933.
|
| 22. |
Dasari VR, Velpula KK, Kaur K,et al. Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP) PLoS One, 2010, 5(7): e11813.
|
| 23. |
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol, 2004, 20: 781-810.
|
| 24. |
Qiao L, Xu ZL, Zhao TJ,et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res, 2008, 18(4): 500-507.
|
| 25. |
Qiao L, Xu ZL, Zhao TJ,et al. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett, 2008, 269(1): 67-77.
|
| 26. |
Abdel aziz MT, El Asmar MF, Atta HM. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res, 2011, 30: 49.
|
| 27. |
Vivanco I, Sawyers CL. The phosphatidylinosito 3-kinase AKT pathway in human cancer, Nat Rev Cancer, 2002, 2(7): 489-501.
|
| 28. |
Parsons DW, Wang TL, Samuels Y,et al. Colorectal cancer: mutations in a signalling pathway. Nature, 2005, 436(752): 792.
|
| 29. |
Khakoo AY, Pati S, Anderson SA,et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med, 2006, 203(5): 1235-1247.
|
| 30. |
Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol, 2007, 211(1): 27-35.
|
| 31. |
Ren C, Kumar S, Chanda D,et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther, 2008, 15(21): 1446-1453.
|
| 32. |
Chen XC, Wang R, Zhao X,et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis, 2006, 27(12): 2434-2441.
|
| 33. |
Kucerova L, Altanerova V, Matuskova M,et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res, 2007, 67(13): 6304-6313.
|
